Changing perceptions in osteoporosis

British Medical Journal

Volumn 318, Issue 7187, 1999, Pages 862-865

  Wilkin, Terence J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; ESTROGEN; HORMONE;

AGING; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; DENSITOMETRY; FRACTURE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; OSTEOCLAST; OSTEOMALACIA; OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY;

BONE DENSITY; BONE RESORPTION; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOMALACIA; OSTEOPOROSIS; RISK FACTORS;

EID: 0033608769     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (17)

1. 1 Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
2. 2 Nordin BE, Horsman A, Marshall DH, Simpson H, Waterhouse GH. Calcium requirement and calcium therapy. Clin Orthop 1979;140:216-39.
3. 3 Kreiger N, Gross A, Hunter G. Dietary factors and fracture in post-menopausal women: a case-controlled study. Int J Epidemiol 1992;21:953-8.
4. 4 Heaney RP. Calcium in the prevention and treatment of osteoporosis. J Intern Med 1992;231:169-80.
5. 5 Cumming RG, Cummings SR, Nevitt MG, Scott J, Ensrud KE, Vogt TM, et al. Calcium intake and fracture risk; results from the Study of Osteoporotic Fractures. Am J Epidemiol 1997;145:926-34.
6. 6 Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333: 1437-43.
7. 7 Peel N, Eastell R. Osteoporosis. BMJ 1995;310:989-92.
8. 8 Christiansen C. Skeletal osteoporosis. J Bone Miner Res 1993;8(suppl 2):S475-80.
9. 9 Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. N Engl J Med 1996;348:1535-41.
10. 10 Hui SL, Slemenda CW, Johston CC Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988;81:1804-9.
11. 11 DeLaet CEDH, Van Hoat BA, Banger H, Hotman A, Pols HA. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997;315:221-5.
12. 12 Kanis J. Treatment of osteoporotic fracture. Lancet 1984;i:27-33.
13. 13 Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late post-menopausal osteoporotic women in response to alendronate treatment. J Clin Invest 1994;79:1693-700.
14. 14 Wilkin TJ. Multi-national, placebo-controlled study of alendronate in post-menopausal osteoporosis - results of 1000 patients from the FOSIT study. Acta Obstet Gynecol Scand 1997;76 (suppl 167):61.
15. 15 Eastell R, Blumsohn A. The value of biochemical markers of bone turnover in osteoporosis. J Rheumatol 1997;24:1215-7.
16. 16 Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson P-G, et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. BMJ 1998;316:1858-63.
17. 17 Department of Health. Clinical guidelines for strategies to prevent and treat osteoporosis, London: Department of Health, 1998. (http:\\www.open. gov.uk/doh/pub/docs/doh/osteoq.pdf)